Coast Independent Review Board Ranks 2356 on the Inc. 5000 List
Inc. magazine ranked Coast Independent Review Board No. 2356 on its 27th annual Inc. 5000 list of the fastest-growing private companies in the U.S.
Inc. Magazine Announces Its 27th Annual List of America’s 5000 Fastest-Growing Private Companies
Colorado Springs, Colo. August 28, 2008– Inc. magazine ranked Coast Independent Review Board No. 2356 on its 27th annual Inc. 5000 list of the fastest-growing private companies in the U.S.
As an Inc. 5000 honoree, Coast Independent Review is now a member of the most influential business clubs in America. The company you keep is notable, as Inc. 5000 alumni include Bill gates of Microsoft, Larry Ellison of Oracle, and many more. The Inc. 5000 is ranked according to percentage revenue growth from 2004 through 2007.
Coast Independent Review Board (IRB) safeguards the rights and well-being of clinical research trial participants for Phase I-IV pharmaceutical, medical device and repository trials. Coast IRB’s associates focus on the customer. “We continue to look for new ways to keep our customer relationships central to our process,” states Darren McDaniel Founder & Managing Director. Additionally, McDaniel promotes educational opportunities to help improve the standards in the industry. This month Coast IRB sponsored a contest to test the ethical savvy of clinical associates. Coast will continue to renovate progress with in the industry by promoting ethical reforms. As part of its continual quest for improvement, Coast IRB is in the process of achieving accreditation with the Association for the Accreditation of Human Research Protection Program (AAHRPP) which ensures high-quality human research protection programs in order to promote excellent, ethically sound research.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
